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Summary Primary colorectal carcinomas of an unselected group of 159 patients 126 of whom could be
curatively resected were examined for the expression of MHC class I antigens with monoclonal antibody
W6/32 directed against a non-polymorphic determinant of HLA-A, B,C heavy chain. One hundred and nine
(68.6%) were found to express HLA-A,B,C antigens in normal quantities, 33 (20.8%) showed a substantial
reduction in expression, while 17 (10%) lacked these antigens either completely or incompletely. The loss of
HLA-A, B,C was inversely correlated with the degree of differentiation. The tendency of mucinous
carcinomas to lack class I antigens was statistically not significant. Tumours with distant metastatic spread at
the time of operation tended to be normal with respect to HLA-A,B,C expression. Within the curatively
resected group, poor differentiation and mucus production were risk factors for survival as could be shown
by life table analysis after a maximum follow-up of 39 months. In contrast, the mode of HLA-A,B,C
expression of the primary tumour did not influence survival within this time of observation. We conclude that
in spite of increasing experimental data suggesting the contrary, the presence or absence of MHC class I
antigens does not seem to profoundly modify tumour biology, at least in human colorectal carcinoma.
Major histocompatibility complex (MHC) class I (HLA-
A, B, C) antigens, composed of highly polymorphic trans-
membrane glycoproteins non-covalently associated with f2-
microglobulin, play an important role in the regulation of
immune functions, as they are part of the target structures
recognized by cytotoxic T-cells (Zinkernagel & Doherty,
1979). HLA-A,B,C antigens are constitutively expressed on
virtually all epithelial cells (Daar et al., 1984) and on B
lymphocytes at all known stages of maturation (Brown et
al., 1979). It has been shown that malignant transformation
of both cell types may be associated with changes in
expression of class I products in the sense of reduction or
complete loss (Fleming et al., 1981; Kabawat et al., 1983;
Whitwell et al., 1984; Ferguson et al., 1985). A pathological
loss of HLA-A,B,C antigens in colorectal carcinoma was
first reported by Daar et al. (1982). We could recently show
that in B-cell lymphomas defective expression of HLA-
A, B, C is correlated with a high grade of malignancy (Moller
et al., 1987) and that a loss or reduction of those antigens in
colorectal carcinoma is inversely correlated with the grade of
differentiation (Momburg et al., 1986). Furthermore, recent
data suggest an association of the mucinous type of
colorectal adenocarcinoma, by itself an unfavourable prog-
nostic parameter, with low expression of HLA class I
antigens (van den Ingh et al., 1987).
This study was undertaken to determine whether the
defective HLA-A, B, C antigen expression on tumours which
is believed to influence immune recognition of neoplastic
cells has effects on important clinical aspects such as the
ability to metastasize and survival.
Materials and methods
Patients
A series of 159 unselected patients who underwent surgery
for colorectal carcinoma between January 1st 1984 and
September 1st 1985 entered the study; final postoperative
analysis of perioperative clinical, surgical and pathological
data led to the characterization of potentially curative
resection in 126 patients while treatment of the other 33 had
to be regarded as palliative (Table I). On April 1st 1987, i.e.
39 months after the first and 19 months after the last patient
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Table I Structure of the entire cohort (159 patients, group A)
and the subgroup with curatively resected tumours (126 patients,
group B)
Group A Group B
Clinicalfeatures
Sex male 91 73
female 68 53
Mean age (yrs+s.d.) 66.3+ 12.1 66.1 + 12.3
Patients in 8th decade of life 57 47
Patients in 9th decade of life 15 11
Deaths during observation
period (39 months) male 37 24
female 28 14
Pathological features
Tumour localization .
Coecum 9 5
Ascending colon 24 19
Hepatic flexure 8 7
Transverse colon 9 6
Splenic flexure 1 I
Descending colon 6 6
Sigmoid flexure 43 32
Rectum 59 50
Tumour type
Adenocarcinoma 115 88
Mucinous carcinoma 35 30
Signet ring carcinoma 1 I
Basaloid carcinoma 1 I
Undifferentiated carcinoma 7 6
Tumour grade
Well differentiated (I) 12 8
Moderately differentiated (II) 118 97
Poorly differentiated (III) 29 21
Tumour stage
I (TI-2 NO MO) 30 29
II (T3-4 NO MO) 48 43
III (TI-4 NI-3 MO) 47 44
IV (T1-4 NI-3 Ml) 34 10
entered the study, every effort was made to verify either the
survival irrespective of the disease state and therapy or the
exact time of death. The data are complete in this respect.
The cause of death could not be established in every case
and was therefore disregarded within the entire group.
Tumours
Immediately after removal, the entire gut specimen was
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examined by one of us (P. M.) and representative samples of
tumour tissue were snap frozen in liquid nitrogen for
immunohistochemical investigation. The tumours whose
primary site and metastatic spread at time of operation were
well documented were typed, graded and staged according to
the UICC classification (Morson & Sobin, 1976; Dukes &
Bussey, 1958; UICC, 1987). The data are listed in Table I.
Immunohistology
Procedure Frozen sections (5pm) were thoroughly air-dried
and then acetone fixed at room temperature for 10min.
After rehydration with PBS, the sections were incubated for
1 h with culture supernatant containing the monoclonal
antibody W6/32 (Barnstable et al., 1978; kindly provided by
the originating laboratory) directed against a monomorphic
determinant on HLA-A,,B,C heavy chains (Malissen et al.,
1982; Kahn-Perles et al., 1987). They were then incubated
with biotinylated anti-mouse Ig (1:50) and streptavidin
peroxidase complex (1:100) (both obtained from Amersham,
High Wycombe, UK) at room temperature for 30min. In
order to avoid cross-reaction, the second antibody was used
in the presence of 5% pooled human IgG. Each incubation
step was followed by a rinse and a further Omin wash with
PBS. The substrate solution containing 0.4mgml-1 3-amino-
9-ethyl-carbazole, 5% N'N-dimethylformamide (both ob-
tained from Sigma, St Louis, MO) and 0.015% H202 in
O.1M acetate buffer, pH 5.0, was applied for 10min and
caused intensely red precipitates at the place of bound
primary antibody. The sections were counterstained with
Harris' haematoxylin and mounted with glycerol gelatine.
A couple of representative immunostainings were repeated
omitting the counterstaining to increase contrast for illus-
tration (Figures 1-3).
Controls Ubiquitously present interstitial dendritic and
lymphoid cells, endothelial cells and fibrocytes served as
intrinsic controls for the immunoreactivity of W6/32. Their
positive staining indicated the reliability of the reaction and
excluded false-negative results. Negative controls were
performed by using irrelevant isotype-matched mouse
monoclonal antibody as primary reagent. No staining was
observed except for the reaction of granulocytes whose
endogenous peroxidase was not destroyed.
Evaluation Staining was evaluated twice by two pathologists
(P.M.; F.M.). As intrinsic positive controls allowed a
gradation of staining intensity, the actual reactivity of the
tumour cells themselves was scored as either strong or weak.
Many tumours contained strongly stained, weakly stained
and non-reactive tumour cells in various proportions that
were scored in a semiquantitative manner. For statistical
analysis these data were divided into three categories:
1. HLA-A, B, C antigen expression within a tumour was
regarded as normal when the entire neoplastic
population was strongly stained and no unreactive
subsets were observed.
2. Class I antigen expression was regarded as reduced
whenever a minority of unstained cells was detectable
while the majority of tumour cells was stained either
strongly or weakly.
3. A severely defective expression of MHC class I genes
corresponding to an (in)complete loss of HLA-A, B,C
antigens was defined whenever the unstained tumour
cell population clearly outnumbered the stained subset
or when the ratio of unreactive and weakly stained
tumour cells was approximately 50:50.
Statistical evaluation
The statistical analysis of the study was carried out by
the computer of the German Cancer Research Center
Heidelberg using the ADAM analysis system drawn up by
its biostatistics department (Weber, 1980, 1982). A Chi2 test
was applied for the analysis of the contingency tables. The
survival curves were calculated by the Kaplan/Meier method
(Kaplan & Meier, 1958).
Results
HLA-A,B, C antigen expression of colorectal carcinomas
Of 159 primary colorectal carcinomas 109 (68.6%) were
found to express HLA-A,B,C antigens in the manner des-
cribed as 'normal' (Figure 1); 33 tumours (20.8%) showed a
reduction in HLA-A, B, C antigen expression (Figure 2)
while 17 (10.7%) tumours were regarded as severely
defective, implying an (in)complete loss of antigen expression
(Figure 3). Within the group of curatively operated patients
a similar distribution was found: 85 (67.5%) tumours were
normal, 25 (19.8%) tumours showed a reduction and 16
(12.7%) an (in)complete loss of HLA-A, B, C antigen
expression.
Analyzing the entire cohort, no correlation could be found
between the mode of HLA-A,B,C antigen expression and
the site of the primary tumour, its stage of local invasiveness
and the lymph node stage. Among the 30 patients with
distant metastasis (stage IV), 29 had primary tumours
which were either HLA-A, B, C-positive or showed a re-
Figure 1 Expression of HLA-A,B,C antigens in cells of this
moderately differentiated mucinous adenocarcinoma was equally
strong as in the stromal cells (arrows), while the mucus is
completely devoid of antigen (cryostat section, aminoethyl-
carbazole [AEC] without counterstain, x 118).
Figure 2 This moderately differentiated non-mucinous adeno-
carcinoma showed a substantial reduction of HLA-A, B,C
antigens within considerable parts of the neoplastic population,
as can be seen by the variably weak (arrows) immunostaining
intensity as compared with the staining of stromal cells. 'a'
marks an artery whose muscular wall is physiologically devoid of
any class I antigens (cryostat section, AEC, without counterstain,
x 79).366 B. STEIN et al.
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Figure 3 This moderately differentiated non-mucinous adeno-
carcinoma showed a complete lack in MHC class I antigen
expression while the reactive stromal cells and some intra-
epithelial lymphocytes (small arrows) strongly expressed HLA-
A, B,C (cryostat section, AEC without counterstain, x 118).
duction in antigen expression, whereas only one patient had
a complete loss of HLA-A, B, C in the primary tumour.
However, this discrepancy in proportion (29/142 vs. 1/17) did
not prove to be statistically significant in the Chi2 test
(P=0.148). Regarding the tumour type, mucinous adeno-
carcinomas showed an (in)complete loss of HLA-A, B, C
in 6/34 (17.6%) cases compared with only 11/125 (8.8%)
in the group of non-mucinous adenocarcinomas. Again, this
discrepancy in proportion was not statistically significant
(P=0.079).
A good correlation, however, could be found for HLA-
A, B, C antigen expression and grade of differentiation
(Table I). The reduction and the (in)complete loss of HLA-
A, B, C antigen expression strongly correlated with poor
differentiation (P=0.0061; P=0.0028 on the basis of the
126 curatively operated patients). A similar significance
(P=0.0036; P=0.0053 on the basis of the 126 curatively
operated patients) could be obtained when the cases with
(in)complete loss of HLA-A, B, C antigens were compared
with the total remaining group.
Survival analysis
The survival analysis calculated on the basis of 159 patients
showed diverging survival curves for the tumour grade of
differentiation, grade I having the most slowly, grade III the
most rapidly declining curve. The same was true for the
curative resection group of 126 patients (Figure 4a) although
a curve was not obtained for grade I since only one death
occurred in this cohort. A second parameter in terms of
survival was the tumour type; patients with mucinous
carcinomas were found to be prone to a shorter survival
than the other group of non-mucinous tumour types taken
together (Figure 4b). No discriminating effect on survival,
however, could be detected when attention was focussed on
the three modes of HLA-A, B, C antigen expression. In fact
the three resulting curves were very much alike in both the
entire group and the curative resection group (Figure 4c). In
the attempt to narrow down further possible high-risk
criteria, the HLA-A, B, C-antigen-negative tumour group was
compared with the combination of normal and reduced
antigen expression on the one hand, and the HLA-A, B,C-
antigen-positive tumour group was compared to the joint
group of reduced and (in)complete antigen expression on the
other. However, neither setting proved to contribute to
differences in survival.
In summary, the reduction and (in)complete loss of HLA-
A, B, C antigen expression in primary colon carcinoma,
although highly correlated with the poorer grade of its
histomorphological differentiation, did not prove to be a
prognostic parameter for survival.
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Figure 4 Overall survival curves calculated on the basis of a
group of 126 curatively resected patients, displaying the depen-
dency (a) on the grade of differentiation (tumour grading: ....
grade II; - grade III); (b) on the presence/absence of mucus
production (tumour typing:.... adenocarcinoma; - mucinous
adenocarcinoma), and; (c) on the mode of HLA-A, B,C antigen
expression of the colorectal carcinoma primary lesion (HLA-
A, B,C expression: .... (in)complete loss; - normal or reduced).
Discussion
Our study aiming at the evaluation of HLA-A, B, C
expression as a prognostic parameter is based upon an
unselected group of colorectal cancer patients. With regard
to its epidemiologic and pathological structure (Table I), the
cohort is comparable to those reported from Rochester
(Moertel et al., 1986), Edinburgh (Freedman et al., 1984),
London (Jass et al., 1986), Padova (Corlon et al., 1984) and
Sydney (Chapuis et al., 1985). This is important to note in
view of the reliability of our statements on HLA-A, B, C
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antigen expression. One of our central findings is that
defective class I antigen expression is correlated with a poor
degree of differentiation, as already reported recently after
statistical analysis of a minor subset of the tumour group
presented herein (Momburg et al., 1986). In this study, an
association between defective HLA-A, B, C antigen expres-
sion and the mucinous type of adenocarcinoma as suggested
by van den Ingh et al. (1987) was not observed. There was a
tendency in this direction which, however, did not achieve
statistical significance.
On malignant cells, surface expression of class I antigens
may be critical for the recognition of tumour and/or virus
associated antigens by cytotoxic T-cells and subsequent
tumour cells lysis (Zinkernagel & Doherty, 1979). It is
therefore suggested that tumour cell variants with low or
lacking class I antigen expression arise by immunoselection
(Sanderson & Beverley, 1983). Defects in class I antigen
expression on tumour cells could offer growth advantages
over other subpopulations with normal levels of expression
(Gooding, 1982; Schmidt & Festenstein, 1982; Bernards et
al., 1983). In experimental tumour models, a reversal of
tumourigenicity could be demonstrated after transfection of
class I genes into cell lines which do not express the genes
constitutively (Hui et al., 1984; Tanaka et al., 1985; Wallich
et al., 1985). Following this line of argument, tumours
lacking class I antigens should be prone to take a more
unfavourable clinical course as compared to those with
normal expression. Although we are well aware that taking
survival regardless of the cause of deaths as the only test
parameter is a very stringent condition, our present data
apparently fail to support this concept. It is even conceivable
that the contrary may be true. Murine lymphoma cells
selected for loss in class I antigen expression were found to
be less malignant after inoculation in syngeneic hosts that
were wild-type cells. The rejection of such cells was found to
function via non-adaptive mechanisms (Karre et al., 1986).
Likewise, induction and/or enhancement of class I products
of non-murine melanoma cells increased the number of
metastases in inoculated animals; tumour cell elimination of
class I antigen deficient cells was due to rapid triggering of
natural killer cells (Taniguchi et al., 1985, 1987). Using
human T and B lymphoblastoid cell lines as targets, Storkus
et al. (1987) observed susceptibility of natural killer cells to
vary inversely with HLA-A, B,C antigen expression of target
cells. We found that patients with distant metastases had
normal amounts of HLA-A,B,C antigens in their primary
tumours in 29/142 cases while only 1/17 patients with stage
IV disease had a primary lacking class I gene products.
Based on the experimental data just cited, tumours ex-
pressing class I antigens might fail to induce a natural killer
reaction and thus have a better chance to cause distant
metastases. However, for the time being we conclude from
our data that presence or absence of MHC class I antigens
does not profoundly modify tumour biology at the clinical
level, at least in human colorectal carcinoma. Nevertheless,
further studies on still larger numbers of patients and longer
follow-up periods are needed to clarify this issue.
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